FindTrial
Sign In

Clinical study to assess efficacy and safety of shoe odour dusting powder for management of general foot odour while wearing Shoes.

A single-center, two arm intra-participants comparison, open-label pilot study to evaluate efficacy and safety of Shoe Odour Dusting Powder formulation for the management of general foot odour while wearing shoes. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/03/107203
Enrollment
22
Registered
2026-03-30
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Shoe odour dusting powder: Shoe odour dusting powder to be applied on right shoe daily once a day for 14 days. Control Intervention1: NIL: NIL

Sponsors

Endeavour Consumer Health.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Males or females aged of 19-65 years (both inclusive) having the problem of sweat and bad odour while wearing shoes. 2. Participants wearing fully closed-off shoes throughout the day for longer duration (i.e. minimum 6-8 hours) on daily basis for work or sports or recreation activities. 3. Participants wearing shoes made of fabric or material that restricts air circulation. 4. Participants willing to stop using any other product similar to study product on feet or in the shoes throughout the study period. 5. Participants willing to give written informed consent and adhere to study procedure. 6. Participants willing to come for visits at the site as per protocol. 7. Participants willing to use the investigational product as instructed per protocol.

Exclusion criteria

Exclusion criteria: 1. Pregnant, lactating women. 2. Participants who wear shoes only for a few hours per day, such as those who wear them briefly at the office and remain without shoes for the rest of the day. 3. Participants allergic to any constituents of formulation. 4. Participants having a known history of skin sensitivity or allergy. 5. Currently, or within the past 30 days, enrolled in a different clinical investigation. 6. Unable or unwilling to provide written informed consent for participation in the study. 7. Participants suffering from chronic illness or any other condition that, in the opinion of the investigator, may compromise the safety and compliance of the participant or preclude the study.

Design outcomes

Primary

MeasureTime frame
Assessment of shoe odour â?? self reported vs assessor, Assessment of shoe moisture level (sweat) â?? self reported vs assessorTimepoint: Day 1 and Day 14—

Secondary

MeasureTime frame
Assessment of Feedback QuestionnaireTimepoint: Day 14;Evaluation of safetyâ?? self reported vs assessor, Adverse eventsTimepoint: Day 1 & Day 14—

Countries

India

Contacts

Public ContactMrs Aditi Vaidya

ProRelix services LLP

s.thasma@prorelixresearch.com8124806366

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 11, 2026